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Studies conducted during the past 25 years to investigate the possible relationship between 
onchocerciasis and epilepsy have led to contradictory results. In the present study aimed at contributing o the 
investigation of a possible relationship between onch cerciasis and epilepsy, we proceeded to purify and 
characterize circulating O. volvulus antigens from sera of onchocerciasis patients withand without epilepsy. 
Out of 539 onchocerciasis patients included in the study, sera from 78 epileptics and 20 non epileptics with 
high antigen titres were separately pooled and subjected to affinity purification using immunosorbent columns 
prepared using human and rabbit anti-O. volvulus IgG antibodies. Eluates of purified circulating O. volvulus 
antigens were concentrated, and then the protein contents were determined using the Bradford method. The 
antigenicity of the purified antigens was evaluated in a direct ELISA using onchocerciasis patient sera. Finally, 
the molecular composition of the purified proteins was determined by SDS-PAGE. The purified antigens were 
highly antigenic and there was no significant difference in the reaction profiles of the two groups or categories 
of patients. SDS-PAGE analysis showed that the purified antigens ranged from 31.63 to 102.40 KDa and there 
was no difference in the molecular composition of antigens purified from sera of the two classes of patients. 
Based on this antigen profiling between epileptic and non-epileptic onchocerciasis patients, we cannot 
conclude with certainty whether onchocerciasis is really a cause of epilepsy in areas where it is hyperendemic 
as predicted by some epidemiological studies.  
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Onchocerciasis or “river blindness” is 
a parasitic disease caused by the filaral worm 
Onchocerca volvulus, and transmitted by the 
bite of a blackfly, Simulium. It causes serious 
cutaneous lesions and can involve in its final 
phase, an irreversible blindness. It is estimated 
that about some 40 million people in the 
world currently suffer from the disease, 
among which the majority are in tropical 
Africa (Pion et al., 2009). Studies carried out 
in several African countries indicate, that 





onchocerciasis hyperendemic zones also have 
a high prevalence of epilepsies (World Health 
Organization, 1999).  
Epilepsy is an affection due to an 
abnormal, sudden and excessive electric 
discharge which comes from an injured area 
of the brain, called the electric focus. This 
cerebral attack is a type of neurological 
disease comparable with an electric storm 
occurring in the brain, and which can be more 
or less violent, localised and frequent 
(Tecoma and Corey-Bloom, 2009). According 
to Pion et al. (2009), epilepsy is particularly 
common in tropical areas and one main reason 
for this is that many endemic infections have 
neurological consequences. There are no 
geographical, social or racial boundaries to the 
disease and everyone can suffer from it. In 
addition, the medical, social and demographic 
burden of epilepsy remain substantial in 
tropical countries where it is often seen as a 
contagious condition and where the aetiology 
is often undetermined. The causes of the 
disease are multiple, including those due to 
infections affecting the brain such as the 
presence of Taenia solium metacestodes in the 
brain, leading to neurocysticercosis which is 
one of the major causes of epilepsy in areas 
where cysticercosis is endemic (De 
Bittencourt et al., 1996; Carpio et al., 1998).  
For several decades, field researchers 
have reported some overlapping between the 
geographical distribution of epilepsy and 
onchocerciasis. To this effect, the question of 
the existence of a causal relationship between 
onchocerciasis and epilepsy has been the 
subject of many studies, essentially based on 
epidemiologic surveys. However, the results 
obtained up to date are controversial and 
many unclarified points persist. The kind of 
relationship that exists between these two 
diseases, as well as the epileptogenic nature of 
O. volvulus, need to be explained. We 
undertook the present study to purify and 
characterise O. volvulus antigens from 
epileptic and non-epileptic onchocerciasis 
patients, so as to certify whether or not the 
antigen profiles differ in the two groups of 
onchocerciasis patients, as this may give us a 
clue as to the role of onchocerciasis in the 
development of epilepsy in areas where the 
disease is hyperendemic. 
MATERIALS AND METHODS  
Study subjects 
Subjects included in this study 
comprised epileptics and non-epileptics from 
the onchocerciasis endemic localities of 
Batibo-Widikum in the North-West region 
and Bangoua in the West region of Cameroon. 
After an information campaign by medical 
authorities only those from whom we had 
informed consent were included in the study. 
Patient identification was done on the basis of 
clinical signs of the two diseases. It is 
necessary to note here that an interview was 
carried out for the purpose of obtaining 
information on the age of the patient, age at 
which epileptic seizures began, their 
manifestations, their frequency, and possibly 
the responsible factors. A total of 539 
onchocerciasis subjects comprising 387 
epileptics from Batibo-Widikum and 54 from 
Bangoua, as well as 98 non-epileptics from 
Bangoua were included in the study. 
 
Blood collection and sera preparation 
Five millilitres (5 ml) of blood were 
collected in dry centrifuge tubes by veno-
puncture at the level of the arm. The blood 
was transported to the laboratory and allowed 
to clot overnight at +5 °C in a refrigerator, 
then centrifuged at 1500 rpm for 15 minutes 
and the supernatant (serum) collected and 
stored at -20 °C until use.  
Negative control sera for this study 
consisted of sera from 65 European children 
who had never been exposed to 
onchocerciasis and showed no symptoms or 
signs of epilepsy.  
 
Identification of O.volvulus seropositive 
patient sera by antigen detection ELISA   
(sandwich-ELISA) 
The Sandwich-ELISA technique was 
essentially carried out as previously described 
(Tume et al., 1997), using O. volvulus-specific 
anti-Oncho-C27 IgG antibodies, with all 
incubations done at 37 °C on an orbital 
shaker. The anti-Oncho-C27 IgG, was diluted 
to a final concentration of 1 µg/ml in 0.1M 
Carbonate/Bicarbonate buffer pH 9.6, and 100 
µl dispensed into each well of microtitre 
plates, and incubated for 60 minutes at 37 °C. 
Plates were emptied of their contents, washed 





with Phosphate-buffered saline (PBS), pH 7.2, 
containing 0.05% Tween-20 (PBS-T), and 
blocked by incubating for 45 minutes at 37 °C 
with 150 µl/well of blocking buffer (0.01% 
New Born calf serum in PBS-T). The contents 
of each plate were again discarded and 
replaced with 100 µl/well of patient (test) or 
control sera. Plates were incubated for 60 
minutes at 37 °C, then emptied and washed 
thoroughly as above. One hundred microlitres 
(100 µl) per well of biotinylated anti-Oncho-
C27 IgG antibodies diluted 1000-fold in 
blocking buffer were introduced, and then the 
plates were incubated for 60 minutes at 37 °C. 
They were emptied and washed thoroughly 
again as above. One hundred microlitres (100 
µl) of peroxidase-conjugated streptavidin 
diluted 3000-fold in blocking buffer were then 
dispensed per well, and incubated for 30 
minutes at 37 °C. The plates were once again 
thoroughly washed and further incubated in 
the dark at room temperature with 100 µl/well 
of peroxidase substrate (O-phenylene 
diamine), prepared according to the 
manufacturer (Sigma). The incubation lasted 
for about 20 minutes during which time a 
significant colour change of the substrate 
occurred in serpositive wells. Reactions were 
stopped by adding 25 µl/well of 4M Sulphuric 
acid (H2SO4), and the absorbance values 
determined spectrophotometrically at 492 nm 
using an automated ELISA plate reader. 
All the above incubation steps, except that of 
the substrate were carried out at 37 °C with 
gentle shaking on a rocking platform. 
The cut-off value was established as the mean 
plus 2 times the standard deviation of the 
absorbance values for the 65 negative control 
sera (XNeg + 2SD). 
Seropositive sera from epileptics 
were pooled into one lot and those from non-
epileptics into another lot, then labelled and 
stored at -20 ºC. 
 
Purification of O. volvulus circulating 
antigens by affinity chromatography 
The immunoadsorbent columns were 
prepared using the inert matrix Sephacryl S-
100 gel, onto which human anti-O.  volvulus 
IgG on the one hand, and  rabbit anti-O. 
volvulus IgG antibodies on the other, were 
coupled. The activation and the coupling were 
carried out as previously described (Sanderson 
and Wilson, 1971; Wilson and Nakane, 1976; 
Tume et al., 1997). Purification of the 
circulating O. volvulus antigens was made 
from the onchocerciasis-epileptic and 
onchocerciasis-non-epileptic sera using the 
two types of immunoaffinity columns. In each 
case, 10 ml of the pooled serum were thawed 
and divided into two equal volumes (5 ml 
each), one for purification through the human 
anti-O. volvulus IgG column and the other 
through the rabbit anti-O. volvulus IgG 
column. The affinity chromatography was 
done as previously described (Ngu et al., 
1989). The bound O. volvulus antigens were 
eluted  using acetate buffer (1.5M Acetic acid, 
0.5M NaCl, pH 2.5). The protein-containing 
eluates were pooled and dialysed against 2 
litres of PBS with two buffer changes, and 
then concentrated using sephadex G25 
powder. 
The protein concentration of each 
antigen preparation was determined using the 
Bradford method (1976), and the samples 
were aliquoted and stored frozen at -20 °C for 
subsequent characterisation . 
 
Characterization of circulating O. volvulus 
antigens 
Comparative antigenicity of purified O. 
volvulus antigens 
The antibody detection ELISA 
technique used was essentially carried out as 
previously described (Tume et al., 1997), with 
some modifications. The purified antigen, in 
each case was diluted to a final concentration 
of 1 µg/ml in 0.1M Carbonate/Bicarbonate 
buffer pH 9.6, and 100 µl dispensed into each 
well of microtitre plates, and incubated for 45 
minutes at 37 °C. Plates were emptied, 
washed with Tris-buffered saline (pH 7.2) 
containing 0.05% Tween 20 (TBS-T), and 
blocked by incubating for 45 minutes at 37 °C 
with 150 µl/well of blocking buffer (0.01% 
New Born calf serum in TBS-T). The contents 
of each plate were discarded again and 
replaced with 100 µl/well of either control 
sera, onchocerciasis-epileptic sera or 
onchocerciasis-non epileptic sera, each diluted 
1000-fold in blocking buffer above. Plates 
were incubated for 60 minutes at 37  °C, then 
emptied and washed thoroughly as above. One 





hundred microlitres (100 µl) of peroxidase-
conjugated goat anti-human IgG antibodies 
diluted 3000-fold in blocking buffer was then 
dispensed per well, and incubated for 15 
minutes at 37 °C. The plates were once again 
thoroughly washed and incubated at room 
temperature with 100 µl/well of peroxidase 
substrate (O-phenylene diamine), prepared 
according to the manufacturer (Sigma). After 
colour development, the reactions were 
stopped by adding 25 µl/well of 4M Sulphuric 
acid (H2SO4) and the absorbances read at 492 
nm using an ELISA plate reader. 
All the above incubation steps, except that of 
the substrate were carried out with gentle 
shaking on a rocking platform. 
 
SDS-PAGE analysis of purified antigens 
This electrophoretic analysis was 
done as previously described (Towbin and 
Gopdon, 1979; Tume, 1993). Briefly, a 15% 
reducing acrylamide gel was introduced into 
an electrophoresis tank containing the 
migration buffer (25 mM Tris/192 mM 
glycine/0.1% SDS). Four volumes of purified 
antigens from the two patient categories and 
the two types of affinity columns were each 
mixed with one volume of 5X concentrated 
Gel Loading Buffer (GLB) then heated for 5 
minutes at 95 ºC. The samples were loaded 
into the gel wells alongside the Molecular 
Weight protein markers (Fermentas) and the 
electrophoresis carried out for 2 hours at 90 
mA. The gel was then removed and stained 
with Coomassie Brillant blue R-250 and then 
destained as previously described (Towbin 
and Gopdon, 1979 and Tume, 1993). 
The relative mobilities of the 
Molecular Weight standards and the protein 
bands for each purified antigen sample were 
then calculated. A standard curve of the 
relative mobilities versus log10 of molecular 
weight of standards was drawn and used to 
determine the corresponding molecular weight 
of each purified protein band. 
 
Statistical analysis 
The data obtained were analyzed 
using the software SPSS 10.0 for Windows, 
and the data expressed in the form of Mean ± 
Standard Deviation. All the statistical analyses 
were done using the Student t test to the 
threshold of 5%. 
 
RESULTS 
Detection of circulating O. volvulus 
antigens in patient sera 
Table 1 presents the seroprevalence 
of O. volvulus antigens in the study subjects 
per locality. Seropositivity to O. volvulus 
antigens was defined relative to a threshold or 
cut-off value, here defined as the mean 
absorbance of negative controls, plus 2 times 
the standard deviation (XNeg
 + 2SD). Based on 
this, all test subjects whose optical densities 
are greater than this threshold of detection are 
declared O. volvulus seropositive and all those 
with the optical density below the threshold 
are declared seronegative. 
According to Table 1, 19.12% of sera 
from epileptics from Batibo-Widikum tested 
positive for circulating O. volvulus antigens, 
whereas in Bangoua with a mixed population 
of epileptics and non epileptics, only 7.4% of 
epileptics were seropositive. Globally, of the 
539 onchocerciasis patients comprising 441 
epileptics and 98 non-epileptics included in 
the study, 78 (17.7%) of the epileptics and 20 
(20.4%) of the non-epileptics were 
seropositive for O. volvulus antigens, giving a 
total prevalence of circulating O. volvulus 
antigens in the study population of 18.2%. No 
significant difference (P>0.05) in 
seroprevalence was observed between 
epileptics (17.7%) and non epileptics (20.4%). 
Also, the mean absorbances characteristic of 
the antigen levels in the two study populations 
did not show any significant difference 
(P>0.05). 
 
Characterization of circulating O. volvulus 
antigens 
Antigenicity of purified O. volvulus antigens 
Table 2 presents the antigenicity of 
purified O. volvulus antigens with sera from 
onchocerciasis patients presenting with or 
without epilepsy. Antigenicity of O. volvulus 
antigens was defined relative to a threshold or 
cut-off value, here defined as the mean 
absorbance of negative controls, plus 3 times 
the standard deviation (XNeg
 + 3SD). 


















Mean of optical density (X ± SD) per 
status 
Cut-off value 
(XNeg + 2SD) 
 E+ E- E+ E- E+ E- E+ E-  
Batibo-Widikum 387 / 74 / 19.1 / 0.645 ± 0,015  NA 
Bangoua 54 98 04 20 7.4 20.4 0.545 ± 0.013 0.590 ± 0.085 NA 
sub-totals 441 98 78 20 17,7 20.4 / / NA 
TOTAL 539 98 18,2 / NA 
Negative controls 65 NA NA 0.127 ± 0.032 0.191 
E+: Epileptics;  E-: Non epileptics. 
XNeg + 2SD: Mean absorbance of negative controls plus 2 times the Standard Deviation. 
 
 













Mean of optical density (X ± SD) per 
status 
Cut-off value 
(XNeg + 3SD) 
 E+ E- E+ E- E+ E- E+ E-  
Batibo-Widikum 200 / 200 / 100 / 1.338 ± 0.883  NA 
Bangoua 50 55 50 55 100 100 1.450 ± 0.849 1.381 ± 0.843 NA 
sub-totals 250 55 250 55 100 100 / / NA 
TOTAL 305 305 100 / NA 
Negative controls 65 NA NA 0.198 ± 0.053 0.357 
E+: Epileptics;  E-: Non epileptics. 
XNeg + 3SD: Mean absorbance of negative controls plus 3 times the Standard Deviation. 





Table 2 shows that, 100% of 
epileptics from Batibo-Widikum presented 
with circulating O. volvulus antibodies in their 
sera. In Bangoua with a mixed population of 
epileptics and non epileptics, 100% of 
epileptics were seropositive for circulating O.
volvulus antibodies. Globally, 100% of 
epileptics in the entire study population have 
been, exposed at least once, to O. volvulus 
worms during their lifetime. 
 
SDS-PAGE 
Electrophoretic separation of the 
various protein components of the antigens 
immunosorbed from sera of the two patient 
categories showed that the purified O. 
volvulus antigens were composed of proteins 
ranging in molecular weight from 31.63 to 
102.40 KDa, and there was no difference in 
the protein profiles of circulating O. volvulus 
antigens purified from the two patient 
categories and using the two immunosorbent 
columns (results not shown).  
  
DISCUSSION 
The aim of this study was to 
contribute to the understanding of the 
relationship between onchocerciasis and 
epilepsy by evaluating the profile of antigens 
purified from epileptic and non-epileptic 
onchocerciasis patient sera, as well as the 
antigenicity of these purified antigens vis a vis 
onchocerciasis patient sera from epileptics and 
non epileptics. 
Our results showed no significant 
difference in the levels of seroprevalence of 
O. volvulus antigens between the sera of 
epileptic and non-epileptic onchocerciasis 
patients. These findings correlate with those 
of Kaiser et al. (2011) in which they found no 
significant difference in the skin microfilarial 
load of epilepsy patients compared to the non-
epileptic controls. Indeed, studies of Kabore et 
al. (1996), Druet-Cabanac et al. (1999) and 
Farnarier et al. (2000) undertaken in different 
geographical areas that are both hyperendemic 
for onchocerciaisis and with high epilepsy 
prevalences did not conclude that there is a 
relationship between the two diseases. 
However, other studies including those of 
Ovuga et al. (1992), Kipp et al. (1994), Kaiser 
et al. (1996) and Newell et al. (1997) 
supported the existence of such a relationship. 
In addition to these conflicting findings, we 
do not have any information on the exact 
chronological order of occurrence of the two 
diseases among the study populations. In fact, 
if onchocerciasis was the first disease 
affecting these patients, its implication as the 
aetiological agent of epilepsy could be 
ascribed. On the other hand, if epilepsy was 
the first disease to affect these patients, then 
the possible role of onchocerciasis in 
epilepsies could be highlighted by an increase 
in the severity of seizures. The existence of no 
significant difference in the levels of 
seroprevalence between the two groups of 
patients (17.7% prevalence among epileptics 
and 20.4% among non-epileptics) suggests 
that there may exist no correlation between 
their onchocercal infection and the 
development of epilepsy. Although in a study 
using magnetic resonance imagery (MRI) and 
cerebrospinal fluid examination (Kaiser et al., 
2000), no O. volvulus parasites were found in 
the brains of epileptics from an onchocerciasis 
endemic area, it is likely that antigenic 
components rather than the intact parasites 
may be at the origin of epilepsy in some 
patients. 
In a recent review, Wagner and 
Newton (2009) raised the interesting 
hypothesis that immunological responses to 
helminths including O. volvulus, might be 
involved in the pathogenesis of epilepsy. This 
correlates very well with findings from 
previous studies which had shown that 
immunological mechanisms including the 
production of some cytokines are implicated 
in the occurrence of certain epilepsies 
(Newton and Forster, 1996). Moreover, it was 
equally shown that cytokines play a role not 
only in epilepsies (Aarli et al., 2003) but also 
in onchocerciasis (Ward et al., 1988; King and 
Nutman, 1991; Soboslay et al., 1992; Chan et 
al., 1993). Therefore, the implication of 
onchocerciasis in occurrence of epilepsies 
could not only be of direct nature through the 





various ways by which circulating O. volvulus 
antigens or O. volvulus microfilariae would 
induce a hyperexcitability of a more or less 
extended neuron population (Molyneux et al.,
1989; Newton and Foster, 1996), but also of 
indirect nature through the immunological 
mechanisms involving IgE (Buttner et al., 
1982) and cytokine production ((Molyneux et 
al., 1989; Finkelman et al., 1991; Modlin and 
Nutman, 1993; Newton and Foster, 1996). 
Our study also showed a very low 
prevalence of O. volvulus antigens within the 
epileptic sera. This low prevalence rate 
suggests that either the epilepsy in 
seronegative epileptics may have a different 
aetiological origin or that onchocerciasis may 
not be a cause of epilepsy. Given that one 
major occupation of people in the Batibo-
Widikum area is pig rearing, it is likely that 
neurocysticercosis could be at the origin of 
their epilepsy; alternatively, their epilepsy 
could be of a mixed aetiology arising from 
combined infection with O. volvulus and 
Taenia solium. However, even though the 
connection between onchocerciasis and 
epilepsy may be influenced by the presence of 
other endemic diseases known to be a cause of 
epilepsy especially cysticercosis (Kaiser et al., 
2010; Katabarwa et al., 2008), a study by 
Kaiser et al. (2008) in areas where a 
relationship between onchocerciasis and 
epilepsy had been found, do not support the 
hypothesis that neurocysticercosis could be 
the cause of onchocerciasis-associated 
epileptic seizures. 
We also observed no difference in the 
banding pattern of purified antigens from 
epileptic and non-epileptic sera. This 
observation shows that there may exist no 
difference in the antigens found in the two 
groups of patients, and thus suggests that if 
there exists a difference in the molecular 
composition of the O volvulus antigens 
circulating in the sera of the two groups of 
patients, this difference might not be at the 
macromolecular level but rather at the level of 
the antigenic epitopes constituting the antigen 
molecules. 
This study thus showed that there is 
no significant difference in antigen levels 
circulating in the sera of epileptics and non-
epileptics, and also that there is no difference 
in the molecular composition of these 
antigens. Also, a very low prevalence of O.
volvulus circulating antigens was observed 
among the sera of epileptic patients. 
On the basis of the O. volvulus 
antigen profiling between epileptic and non-
epileptic onchocerciasis patients obtained in 
this study, we cannot conclude with certainty 
whether onchocerciasis is really a cause of 
epilepsy in areas where it is hyperendemic as 
predicted by epidemiological studies. Further 
research is thus needed for a better 
understanding of the neurological 
pathogenicity in onchocerciasis. 
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